#宝藏兴趣攻略#
From 2015 to 2017, Hansoh sales expenses were 2.24 billion yuan, 2.378 billion yuan and 2.704 billion yuan respectively; The selling expense ratio was 44.4%, 43.77% and 43.71%
Its sales expenses mainly include marketing and promotion expenses, travel expenses, staff costs, etc., among which marketing and promotion expenses are the highest, accounting for 78.4% in 2017
Note that this sales expense ratio is very high, and it can be ranked 34th in the sales expense ratio ranking of A-share pharmaceutical companies. Compare companies in the same industry and take a look:
Hengrui Pharmaceutical - 2015-2017 sales expenses were 3.325 billion yuan, 4.352 billion yuan and 5.189 billion yuan respectively; The sales expense ratios were 37.84%, 39.23% and 37.5% respectively
Hengrui Pharmaceutical - 2015-2017 sales expenses were 3.325 billion yuan, 4.352 billion yuan and 5.189 billion yuan respectively; The sales expense ratios were 37.84%, 39.23% and 37.5% respectively
Humanwell Pharmaceutical - 2015-2017 sales expenses were 1.609 billion yuan, 1.856 billion yuan and 2.606 billion yuan respectively; Selling expense ratios were 16%, 15.05%, and 16.87%
Xianju Pharmaceutical - 2015-2017 sales expenses were 620 million yuan, 776 million yuan, and 939 million yuan respectively; The selling expense ratio was 24.98%, 30.98%, and 32.92%
Eli Lilly - 2015-2017 sales expenses were US$6.533 billion, US$6.452 billion, and US$6.588 billion respectively (equivalent to RMB 42.423 billion, 44.758 billion yuan, and 43.048 billion yuan); The sales expense ratio was 32.73%, 30.87% and 28.81%.
Pfizer - sales expenses from 2015 to 2017 were US$14.809 billion, US$14.837 billion, and US$14.784 billion respectively (equivalent to RMB 101.294 billion, 101.485 billion yuan, and 101.123 billion yuan); Selling expense ratios were 30.3%, 28.1% and 28.1%
From the perspective of the compound growth rate of sales expense rate VS revenue growth rate
Nhwa's sales expenses and revenue are growing simultaneously, while Hengrui, Hansoh and Eli Lilly have reduced their sales expenses while still maintaining revenue growth, indicating that their brand strength and product absorption ability are stronger.
The whereabouts of its investment are basically clear, with a revenue of 6.186 billion yuan a year, of which 7.36% is spent on costs, 9.31% is spent on research and development expenses, 43.71% is spent on sales expenses, and the rest is spent on management expenses, and finally excluding taxes and fees, various expenses, etc., the remaining 25.78% is net profit.
In 2017, the market size of central nervous system drugs in mainland China was 181.1 billion yuan, accounting for 12.7% of the total pharmaceutical market in mainland China, and the compound growth rate is expected to be 9.8% from 2017 to 2022.
Central nervous system drugs are mainly divided into three categories: nervous system drugs, psychiatric drugs, and other drugs.
Among them, the market size of psychiatric drugs reached 20.7 billion yuan in 2017, accounting for 11.4% of the mainland central nervous system drug market, making it the largest sub-market of the central nervous system
It is estimated that from 2017 to 2022, the compound annual growth rate will be 15.1%, which is much higher than the growth rate of the central nervous system diseases market.
Psychiatric drugs can be divided into three categories: anti-schizophrenia, anti-depressant, and anti-anxiety, among which anti-schizophrenia drugs are the largest market segment. Anti-schizophrenia drugs and antidepressants, together account for about 80% of the global psychotropic drug market
Predict the follow-up and listen to the next breakdown
It does not constitute any investment advice, the stock market is risky, and you need to be cautious when entering the market